高级检索
张强, 罗曦, 包永睿, 王帅, 李天娇, 孟宪生. 生物膜仿生纳米制剂研究进展[J]. 中国药科大学学报, 2023, 54(5): 544-552. DOI: 10.11665/j.issn.1000-5048.2023020603
引用本文: 张强, 罗曦, 包永睿, 王帅, 李天娇, 孟宪生. 生物膜仿生纳米制剂研究进展[J]. 中国药科大学学报, 2023, 54(5): 544-552. DOI: 10.11665/j.issn.1000-5048.2023020603
ZHANG Qiang, LUO Xi, BAO Yongrui, WANG Shuai, LI Tianjiao, MENG Xiansheng. Research progress in biomimetic nano formulations of biofilms[J]. Journal of China Pharmaceutical University, 2023, 54(5): 544-552. DOI: 10.11665/j.issn.1000-5048.2023020603
Citation: ZHANG Qiang, LUO Xi, BAO Yongrui, WANG Shuai, LI Tianjiao, MENG Xiansheng. Research progress in biomimetic nano formulations of biofilms[J]. Journal of China Pharmaceutical University, 2023, 54(5): 544-552. DOI: 10.11665/j.issn.1000-5048.2023020603

生物膜仿生纳米制剂研究进展

Research progress in biomimetic nano formulations of biofilms

  • 摘要: 生物膜仿生纳米制剂有低免疫原性、高靶向性以及良好的生物相容性,且可避免被内皮网状系统清除,使其在体内血液循环时间更长。本文主要综述了生物膜仿生纳米制剂的主要类型及各自的优缺点,包括肿瘤细胞膜、红细胞膜、血小板膜、白细胞膜、干细胞膜、细胞外囊泡(外泌体、微囊泡及凋亡小体)、内质网膜以及复合生物膜等。同时针对生物膜仿生纳米制剂的研究现状,对其面临的挑战以及未来发展前景进行了展望,以期为生物膜仿生纳米制剂的进一步研究提供思路。

     

    Abstract: Biomimetic nano formulations of biofilms have low immunogenicity, high targeting, and good biocompatibility, and can avoid being cleared by the endothelial reticular system, thus with in longer blood circulation time in the body.This article mainly reviews the main types as well as advantages and disadvantages of biomimetic nano formulations of biofilms, including tumor cell membranes, red blood cell membranes, platelet membranes, white blood cell membranes, stem cell membranes, extracellular vesicles (exosomes, microvesicles, and apoptotic bodies), endoplasmic reticulum membranes, and composite biofilms, with also a prospect of the challenges facing biomimetic nano formulations of biofilms and their future development based on their current research status, aiming to provide some insight for further research on biomimetic nano formulations of biofilms.

     

/

返回文章
返回